相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Impact of FLT3-ITD length on prognosis of acute myeloid leukemia
Song-Bai Liu et al.
HAEMATOLOGICA (2019)
The importance of FLT3 mutational analysis in acute myeloid leukemia
Mrinal M. Patnaik
LEUKEMIA & LYMPHOMA (2018)
FLT3-ITD positive acute myeloid leukemia: A retrospective analysis of the role of allogeneic transplant and allelic ratio in patient management
Emma Taylor et al.
ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY (2018)
Effect of Sorafenib on the Outcomes of Patients With FLT3-ITD Acute Myeloid Leukemia Undergoing Allogeneic Hematopoietic Stem Cell Transplantation
Li Xuan et al.
CANCER (2018)
Sorafenib promotes graft-versus-leukemia activity in mice and humans through IL-15 production in FLT3-ITD-mutant leukemia cells
Nimitha R. Mathew et al.
NATURE MEDICINE (2018)
FLT3-ITD and its current role in acute myeloid leukaemia
Francisco Alejandro Lagunas-Rangel et al.
MEDICAL ONCOLOGY (2017)
Midostaurin plus Chemotherapy for Acute Myeloid Leukemia with a FLT3 Mutation
R. M. Stone et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
FLT3 inhibitors: clinical potential in acute myeloid leukemia
Marie-Anne Hospital et al.
ONCOTARGETS AND THERAPY (2017)
Efficacy and Feasibility of Sorafenib as a Maintenance Agent After Allogeneic Hematopoietic Stem Cell Transplantation for Fms-Like Tyrosine Kinase 3-Mutated Acute Myeloid Leukemia
Giorgia Battipaglia et al.
CANCER (2017)
FLT3 mutational status is an independent risk factor for adverse outcomes after allogeneic transplantation in AML
Y. Song et al.
BONE MARROW TRANSPLANTATION (2016)
Allogeneic Transplantation in First Remission Improves Outcomes Irrespective of FLT3-ITD Allelic Ratio in FLT3-ITD-Positive Acute Myelogenous Leukemia
Betul Oran et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2016)
Introduction to a review series: the 2016 revision of the WHO classification of tumors of hematopoietic and lymphoid tissues
Mario Cazzola
BLOOD (2016)
Haematopoietic cell transplantation with and without sorafenib maintenance for patients with FLT3-ITD acute myeloid leukaemia in first complete remission
Andrew M. Brunner et al.
BRITISH JOURNAL OF HAEMATOLOGY (2016)
Does FLT3 Mutation Impact Survival After Hematopoietic Stem Cell Transplantation for Acute Myeloid Leukemia? A Center for International Blood and Marrow Transplant Research (CIBMTR) Analysis
Abhinav Deol et al.
CANCER (2016)
Characterisation and Clinical Significance of FLT3-ITD and non-ITD in Acute Myeloid Leukaemia Patients in Kelantan, Northeast Peninsular Malaysia
Noraini Mat Yunus et al.
Asian Pacific Journal of Cancer Prevention (2015)
Secondary mutations as mediators of resistance to targeted therapy in leukemia
Naval Daver et al.
BLOOD (2015)
Is allogeneic transplantation really the best treatment for FLT3/ITD-positive acute myeloid leukemia? A systematic review
Yingying Ma et al.
CLINICAL TRANSPLANTATION (2015)
FLT3-ITD drives Ara-C resistance in leukemic cells via the induction of RUNX3
Anar Damdinsuren et al.
LEUKEMIA RESEARCH (2015)
Quantitative fragment analysis of FLT3-ITD efficiently identifying poor prognostic group with high mutant allele burden or long ITD length
Y. Kim et al.
BLOOD CANCER JOURNAL (2015)
Phase I Trial of Maintenance Sorafenib after Allogeneic Hematopoietic Stem Cell Transplantation for Fms-like Tyrosine Kinase 3 Internal Tandem Duplication Acute Myeloid Leukemia
Yi-Bin Chen et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2014)
Impact of FLT3ITD mutant allele level on relapse risk in intermediate-risk acute myeloid leukemia
David C. Linch et al.
BLOOD (2014)
Differential impact of allelic ratio and insertion site in FLT3-ITD-positive AML with respect to allogeneic transplantation
Richard F. Schlenk et al.
BLOOD (2014)
Treatment With FLT3 Inhibitor in Patients With FLT3-Mutated Acute Myeloid Leukemia Is Associated With Development of Secondary FLT3-Tyrosine Kinase Domain Mutations
Yesid Alvarado et al.
CANCER (2014)
SIRT1 Activation by a c-MYC Oncogenic Network Promotes the Maintenance and Drug Resistance of Human FLT3-ITD Acute Myeloid Leukemia Stem Cells
Ling Li et al.
CELL STEM CELL (2014)
Medium-sized FLT3 internal tandem duplications confer worse prognosis than short and long duplications in a non-elderly acute myeloid leukemia cohort
Magdalena Koszarska et al.
LEUKEMIA & LYMPHOMA (2014)
Sorafenib in Combination With Intensive Chemotherapy in Elderly Patients With Acute Myeloid Leukemia: Results From a Randomized, Placebo-Controlled Trial
Hubert Serve et al.
JOURNAL OF CLINICAL ONCOLOGY (2013)
Molecular analysis of different FLT3-ITD mutations in acute myeloid leukemia
Olga Blau et al.
LEUKEMIA & LYMPHOMA (2013)
Potent Graft-versus-Leukemia Effect after Reduced-Intensity Allogeneic SCT for Intermediate-Risk AML with FLT3-ITD or Wild-Type NPMI and CEBPA without FLT3-ITD
Gaelle Laboure et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2012)
Impact of FLT3 Internal Tandem Duplication on the Outcome of Related and Unrelated Hematopoietic Transplantation for Adult Acute Myeloid Leukemia in First Remission: A Retrospective Analysis
Salut Brunet et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
Effects of intensified conditioning on Epstein-Barr virus and cytomegalovirus infections in allogeneic hematopoietic stem cell transplantation for hematological malignancies
Li Xuan et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2012)
Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet
Hartmut Doehner et al.
BLOOD (2010)
The impact of FLT3 internal tandem duplication mutant level, number, size, and interaction with NPM1 mutations in a large cohort of young adult patients with acute myeloid leukemia
Rosemary E. Gale et al.
BLOOD (2008)
Size of FLT3 internal tandem duplication has prognostic significance in patients with acute myeloid leukemia
DL Stirewalt et al.
BLOOD (2006)
No evidence that FLT3 status should be considered as an indicator for transplantation in acute myeloid leukemia (AML): an analysis of 1135 patients, excluding acute promyelocytic leukemia, from the UK MRC AML 10 and 12 trials
RE Gale et al.
BLOOD (2005)
The structural basis for autoinhibition of FLT3 by the juxtamembrane domain
J Griffith et al.
MOLECULAR CELL (2004)
Revised recommendations of the international working group for diagnosis, standardization of response criteria, treatment outcomes, and reporting standards for therapeutic trials in acute myeloid leukemia
BD Cheson et al.
JOURNAL OF CLINICAL ONCOLOGY (2003)
FLT3 internal tandem duplication in 234 children with acute myeloid leukemia:: prognostic significance and relation to cellular drug resistance
CM Zwaan et al.
BLOOD (2003)
Prognostic significance of activating FLT3 mutations in younger adults (16 to 60 years) with acute myeloid leukemia and normal cytogenetics:: a study of the AML Study Group Ulm
S Fröhling et al.
BLOOD (2002)
Analysis of FLT3 length mutations in 1003 patients with acute myeloid leukemia:: correlation to cytogenetics, FAB subtype, and prognosis in the AMLCG study and usefulness as a marker for the detection of minimal residual disease
S Schnittger et al.
BLOOD (2002)
Prevalence and prognostic significance of Flt3 internal tandem duplication in pediatric acute myeloid leukemia
S Meshinchi et al.
BLOOD (2001)
分享论文
